News Releases

News Releases

Feb 01, 2023

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
Jan 09, 2023

CORRECTING and REPLACING --Merus Provides 2023 Outlook

As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Petosemtamab clinical update planned for first half of 2023 MCLA-129 clinical update planned for second half of 2023 Based on the Company’s current
Jan 08, 2023

Merus Provides 2023 Outlook

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Company’s